A novel gastro-sparing prodrug of rhein and boswellic acid was designed for the management of osteoarthritis and its synthesis, characterization and pharmacokinetic profile is reported. The prodrug was activated by hydrolysis releasing rhein (91%) and boswellic acid (84.37%) in rat blood over a period of 7h upon its oral administration.